Genfit has added a third liver failure candidate to its portfolio courtesy of a licensing deal with Seal Rock Therapeutics potentially worth up to 100 million euros ($107 million) in biobucks.
SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF).
SEATTLE, Oct. 24, 2022 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced oral and poster presentations at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), taking place November 4-8, 2022, in Washington, DC.
SEATTLE, Oct. 19, 2021 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage biotechnology company developing a platform of first-in-class and best-in-class therapeutic kinase inhibitors for treatment of severe fibrotic and inflammatory diseases with limited or no available therapies, today announced completion of the single ascending dose (SAD) portion of its Phase 1 clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 (ASK1) for Non-Alcoholic SteatoHepatitis (NASH) and other liver diseases such as Alcoholic Hepatitis (AH).
Seal Rock Therapeutics, Inc., a clinical stage biotechnology company developing a platform of first-in-class and best-in-class therapeutic kinase inhibitors for treatment of severe fibrotic and inflammatory diseases with limited or no available therapies, today announced dosing of the first healthy volunteer in a Phase 1 clinical trial of SRT-015, a next-generation, liver-selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for non-alcoholic steatohepatitis (NASH) and other liver diseases such as Alcoholic Hepatitis (AH) .